Where does PHAS stock trade?

PhaseBio Pharmaceuticals Inc. (PHAS) is listed on NASDAQ.

What sector and industry is PHAS in?

PhaseBio Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did PhaseBio Pharmaceuticals Inc. go public?

PhaseBio Pharmaceuticals Inc. (PHAS) completed its IPO in 2018.

What are analysts saying about PHAS?

PhaseBio Pharmaceuticals Inc. has had 2 recent analyst actions on file. The most recent action was from Stifel: Hold with a $100.00 price target on 2022-09-28.

What companies are similar to PHAS?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PHAS side-by-side with any of them on Quantisnow.

How can I track PHAS on Quantisnow?

Quantisnow aggregates PhaseBio Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAS to receive live email and push alerts on every new disclosure.

PHAS

NASDAQ

PhaseBio Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2018

$0.07-0.02 (-26.32%)

Follow Website

News25/Ratings2

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

Latest news

25 items

PHAS FAQ

7 questions

What does PhaseBio Pharmaceuticals Inc. do?
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial...
Where does PHAS stock trade?
PhaseBio Pharmaceuticals Inc. (PHAS) is listed on NASDAQ.
What sector and industry is PHAS in?
PhaseBio Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did PhaseBio Pharmaceuticals Inc. go public?
PhaseBio Pharmaceuticals Inc. (PHAS) completed its IPO in 2018.
What are analysts saying about PHAS?
PhaseBio Pharmaceuticals Inc. has had 2 recent analyst actions on file. The most recent action was from Stifel: Hold with a $100.00 price target on 2022-09-28.
What companies are similar to PHAS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PHAS side-by-side with any of them on Quantisnow.
How can I track PHAS on Quantisnow?
Quantisnow aggregates PhaseBio Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAS to receive live email and push alerts on every new disclosure.